neural biomarkers of clozapine response

Conditions: Schizophrenia; Treatment-resistant Schizophrenia; Schizoaffective Disorder

Summary: clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown. the overall goal of this study is to examine the functional neural circuitry that underlies successful treatment with clozapine, which may lead to the identification of biomarkers that will allow for more efficient use of clozapine, as well as additional treatment targets for patients with refractory illness.

a large number of patients with chronic psychotic disorders continue to have symptoms following unsuccessful trials with first-line antipsychotic drugs. for these patients with refractory psychosis, clozapine has consistently demonstrated superior efficacy. clozapine is often underutilized and administered late in a patient's course of treatment, which leads to increased morbidity, unnecessary medication trials, and increased health care expenditure. meanwhile, the mechanism of action underlying clozapine's novel effects remains unknown and has not been studied with modern neuroimaging methods. identifying the neural mechanisms by which clozapine exerts its effects may lead to biomarkers that will facilitate efficient utilization of the drug, and introduce novel treatment targets. in patients with refractory psychotic symptoms, the proposed study will use resting-state and task-based functional mri (fmri) to examine the neural circuitry of efficacious treatment with a trial of clozapine. patients will undergo fmri scanning both before and after 12 weeks of treatment, with the aims of determining: baseline patterns of resting-state functional connectivity and task-based activation that predict response to treatment; and changes in resting-state and task-based functional circuitry associated with efficacious treatment. results of this proposal may lead to biomarkers that will optimize treatment algorithms for psychotic disorders and facilitate drug development for refractory psychosis.

Eligibility criteria:
inclusion criteria: 1. current positive symptoms rated ≥4 (moderate) on one or more of these brief psychiatric rating scale items: hallucinatory behavior, unusual thought content and conceptual disorganization. 2. patient has failed two trials of treatment with antipsychotic drugs and the patient's clinical team is initiating clozapine. 3. age of 18 to 50. 4. patient is competent and willing to sign informed consent. 5. for female patients, negative pregnancy test and agreement to use a medically accepted birth control method. 6. diagnosis of schizophrenia or schizoaffective disorder exclusion criteria: 1. serious neurological or endocrine disorder. 2. any medical condition which requires treatment with a medication with psychotropic effects 3. significant risk of suicidal or homicidal behavior 4. cognitive or language limitations, or any other factor that would preclude subjects providing informed consent 5. contraindications to treatment with clozapine (e.g. failed response in past, or history of adverse reactions to treatment). 6. contraindications to magnetic resonance imaging (e.g. pacemaker). 7. female patients who are pregnant or breast feeding.